NUE

Nuevolution

Market Cap 759.7M

Nuevolution is a Copenhagen-based biopharmaceutical company, co-founded in 2001 by CEO Alex Haahr Gouliaev and today listed in Stockholm, Sweden. NUE uses its proprietary drug discovery platform Chemetics to generate novel small molecule drugs for hard-to-drug disease targets. The platform allows NUE to pursue multiple disease targets cost effectively and offers increased efficiency and quality of drug discovery. The business model revolves around Chemetics and two distinct value-drivers; (1) risk-sharing/”pre-sale” partnership deals to identify drugs for novel targets in collaboration with a partner, and (2) the development and out-licensing of internal projects. Revenues are generated from upfront and milestone payments as well as recurring royalties on future sales. NUE has earned about SEK 525 million in licensing revenue from 17 partner agreements to date and current deal structures offer multiple milestone opportunities in the coming years. The Company has delivered on their IPO promise of delivering deals as they signed a multi-target risk-sharing partnership with Amgen in October 2016 and out-licensed a program to Almirall in December 2016. Given the portfolio approach, NUE does not fall into the category of fully binary biotech companies, but rather into a class of more stable biopharma companies with some growth visibility. 

+ more
Today
Day High
15.70
15.34
Day Low
14.98
Day Open
15.58
Prev Close
15.78
VWAP
15.3
Volume
40K
Turnover
0.614M
Top Broker
VWAP
15.9
Avg Volume
53K
Avg Turnover
0.847M
Top Brokers
NON/AVA
VWAP
16.1
Avg Volume
37K
Avg Turnover
0.603M
Top Brokers
AVA/NON
VWAP
16.5
Avg Volume
37K
Avg Turnover
0.616M
Top Brokers
AVA/NON
52 week summary
Price Range
14.3
Last
24.0
Beta
N/A
Market Cap
759.7M
Total Return
0.9%
Trailing P/E
-5.7
Div Yield
0.0%
Shares Outstanding
49.5M
Next Earnings Date
12 Sep
Stock Exchange
NASDAQ Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.

Relative Price Strength
Change 3 Months -17.4%
Change 12 Months -6.5%
Volume Trend
Average Volume 10 vs 60 Days 41.3%
Price VS
52 Week High -36.1%
50 Day Moving Average -7.8%
200 Day moving Average -9.7%

Add article markers

Compare Nuevolution to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
Last updated: 2018-02-12 Source: Redeye
Major Owners Equity Votes
Sunstone LSV Fund I K/S 20.7%
20.7%
SEB Venture Capital 20.4%
20.4%
Stiftelsen Industrifonden 18.2%
18.2%
SEB Utvecklingsstiftelse 6.6%
6.6%
SEB-Stiftelsen 5.0%
5.0%
Avanza Pension 2.4%
2.4%
LMK Forward 2.3%
2.3%
AAGCS NV RE AACB NV RE EURO CCP 1.4%
1.4%
Nordnet Pensionförsäkrings AB 1.0%
1.0%
Vätterleden AB 1.0%
1.0%
Last updated: 2018-07-14 Source: Redeye
Timeframe Transactions Net Shares
Last 12 weeks
0 Purchases
0
1 Sales
-70,778
Last 24 weeks
0 Purchases
0
1 Sales
-70,778
Report Date Name Position Transaction Shares Chg Est Value (SEK)

Insider trades are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Source: Millistream
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
  • 2015
  •  
  • 0.0%
  • -76.0%
  • 0.0%
  • -428.3%
  • -423.0%
  • -388.2%
  •  
  • -2.01
  • -2.01
  • 0.00
  •  
  • 42.9
  •  
  • -258.4
  • 0.0
  • 0.0
  • 0.0
  • -11.6
  • 2.7
  • 2.8
  • 0.0
  •  
  • 81.3%
  • 100.0%
  • -258
  • -16
  • 0.1
  • 2015
  •  
  •  
  • 263
  • 29
  • 0
  • 0
  • 292
  •  
  • 5
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2
  • 6
  • 0
  • 298
  •  
  •  
  • 1
  • 26
  • 25
  • 52
  • 3
  • 0
  • 0
  • 56
  • 0
  • 0
  • 243
  • 0
  • 243
  • 298
  • 2015
  • 22
  • -117
  • 1
  • -94
  • 7
  • -87
  • -1
  • -88
  • 22
  • -5
  • -71
  • 2015 Q1
  • 4
  • -23
  • -19
  • 0
  • 0
  • 0
  • -19
  • 0
  • 0
  • 0
  • -19
  • 2
  • -17
  • 2015 Q2
  • 6
  • -28
  • -22
  • 0
  • 0
  • 0
  • -22
  • 0
  • 0
  • 0
  • -22
  • 2
  • -20
  • 2015 Q3
  • 1
  • -27
  • -26
  • 0
  • 0
  • 0
  • -26
  • 0
  • 0
  • 0
  • -26
  • 2
  • -24
  • 2015 Q4
  • 11
  • -39
  • -28
  • 0
  • 0
  • 0
  • -28
  • 0
  • 1
  • 0
  • -27
  • 2
  • -26
  • 2016
  •  
  • -27.7%
  • -21.1%
  • 419.8%
  • -42.6%
  • -41.3%
  • -53.1%
  •  
  • -1.51
  • -1.51
  • 0.00
  •  
  • 42.9
  •  
  • -142.9
  • 0.0
  • 0.0
  • 0.0
  • -1.2
  • 2.8
  • 2.8
  • 0.0
  •  
  • 88.7%
  • 100.0%
  • -143
  • 82
  • 0.5
  • 2016
  •  
  •  
  • 148
  • 97
  • 0
  • 0
  • 245
  •  
  • 6
  • 0
  • 0
  • 0
  • 0
  • 0
  • 4
  • 10
  • 0
  • 254
  •  
  •  
  • 1
  • 14
  • 10
  • 25
  • 3
  • 0
  • 0
  • 29
  • 0
  • 0
  • 225
  • 0
  • 225
  • 254
  • 2016
  • 122
  • -174
  • 2
  • -50
  • -16
  • -66
  • -2
  • -67
  • -95
  • -2
  • -164
  • 2016 Q1
  • 6
  • -28
  • -22
  • 0
  • 0
  • 0
  • -22
  • 0
  • -1
  • 0
  • -23
  • 2
  • -21
  • 2016 Q2
  • 3
  • -80
  • -77
  • 0
  • 0
  • 0
  • -77
  • 0
  • 0
  • 0
  • -76
  • 2
  • -75
  • 2016 Q3
  • 2
  • -30
  • -28
  • 0
  • 0
  • 0
  • -28
  • 0
  • 0
  • 0
  • -27
  • 2
  • -26
  • 2016 Q4
  • 111
  • -36
  • 75
  • 0
  • 0
  • 0
  • 76
  • 0
  • 1
  • 0
  • 77
  • -21
  • 56
  • 2017
  •  
  • -69.9%
  • -71.3%
  • -141.7%
  • -980.0%
  • -994.3%
  • -949.8%
  •  
  • -2.74
  • -2.74
  • 0.00
  •  
  • 42.9
  •  
  • -110.6
  • 0.0
  • 0.0
  • 0.0
  • -8.9
  • 0.9
  • 0.9
  • 0.0
  •  
  • 81.2%
  • 100.0%
  • -111
  • 1
  • 0.1
  • 2017
  •  
  •  
  • 115
  • 10
  • 0
  • 0
  • 125
  •  
  • 6
  • 0
  • 0
  • 0
  • 0
  • 0
  • 5
  • 12
  • 0
  • 137
  •  
  •  
  • 1
  • 18
  • 3
  • 23
  • 3
  • 0
  • 0
  • 26
  • 0
  • 0
  • 111
  • 0
  • 111
  • 137
  • 2017
  • 12
  • -134
  • -2
  • -123
  • 6
  • -117
  • 2
  • -115
  • 84
  • -4
  • -35
  • 2017 Q1
  • 2
  • -31
  • -29
  • 0
  • 0
  • 0
  • -30
  • 0
  • 0
  • 0
  • -30
  • 1
  • -29
  • 2017 Q2
  • 6
  • -34
  • -28
  • 0
  • 0
  • 0
  • -29
  • 0
  • 0
  • 0
  • -29
  • 2
  • -27
  • 2017 Q3
  • 2
  • -31
  • -30
  • 0
  • 0
  • 0
  • -30
  • 0
  • 0
  • 0
  • -30
  • 2
  • -29
  • 2017 Q4
  • 3
  • -37
  • -34
  • 0
  • 0
  • 0
  • -34
  • 0
  • 0
  • 0
  • -35
  • 2
  • -33
  • 2018 E
  • 2018 E
  • 2018 E
  • 2018 E
  • 2019 E
  • 2019 E
  • 2019 E
  • 2019 E
  • 2020 E
  • 2020 E
  • 2020 E
  • 2020 E

Estimated Values are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Last updated: 2018-02-12 Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.

Source: Redeye

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.